Co-Authors
This is a "connection" page, showing publications co-authored by LEE M ELLIS and DIPEN MAHESHBHAI MARU.
Connection Strength
1.021
-
Predictive biomarkers for bevacizumab: are we there yet? Clin Cancer Res. 2013 Jun 01; 19(11):2824-7.
Score: 0.465
-
Fusobacterium Nucleatum Subspecies Animalis Influences Proinflammatory Cytokine Expression and Monocyte Activation in Human Colorectal Tumors. Cancer Prev Res (Phila). 2017 Jul; 10(7):398-409.
Score: 0.154
-
Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. Cancer. 2013 Dec 15; 119(24):4231-41.
Score: 0.120
-
Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell. 2013 Feb 11; 23(2):171-85.
Score: 0.115
-
Author Correction: TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature. 2021 Sep; 597(7875):E6.
Score: 0.052
-
MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget. 2016 08 23; 7(34):54627-54631.
Score: 0.037
-
TP53 loss creates therapeutic vulnerability in?colorectal cancer. Nature. 2015 Apr 30; 520(7549):697-701.
Score: 0.034
-
Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):824-30.
Score: 0.022
-
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008 Nov 20; 26(33):5344-51.
Score: 0.021